CIPLA LIMITED

The global OTC drug and dietary supplement market was valued at $310.96 billion in 2023, expected to reach $438.25 billion by 2028, and $632.1 billion by 2033. Factors driving growth include health consciousness, dietary supplement demand, government initiatives, aging population, and e-commerce expansion. Key segments include vitamin and dietary supplements, tablets, and pharmacies. North America leads the market, with Asia-Pacific and Africa expected to grow fastest.

AL Ideathon 2024 at Novotel, Hyderabad, showcased AI, ML, NLP, and automation applications in pharma, receiving 544+ global submissions. Industry leaders discussed digital transformation, AI in manufacturing, and R&D impact. Top innovators were recognized, with Anurag Gokhale winning the Golden Innovation Award for voice search-enabled systems.

Hetero and Dr Reddy’s sign non-exclusive, royalty-free licensing agreement with Gilead Sciences to manufacture and distribute lenacapavir, an HIV treatment drug, in 120 low- and lower-middle-income countries, including India. Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is currently under investigation for HIV prevention. The agreement aims to make the drug accessible at affordable costs, with Indian generic manufacturers potentially producing it for $100 per person per year.

Indian pharma giants focus on quality over quantity, with complex product filings increasing. US generics sales show slight growth, and regulatory challenges ease. Nomura recommends Lupin for its upcoming launches and stable market shares, while noting setbacks. Sun Pharma's specialty segment growth slows, and Dr Reddy's faces market share declines. Cipla and Zydus Lifesciences show growth but face inspection and competition challenges.

India, known as the 'Pharmacy of the World,' supplied vaccines and medicines globally during COVID-19, fulfilling 40% of U.S. generic drug demand and 25% of U.K. medicines. The $50 billion industry is projected to grow to $130 billion by 2030, driven by companies like Mankind Pharma, which acquired Bharat Serums and Vaccines for ₹13,600 crore. India faces regulatory challenges including complex drug approvals, IP issues, and API dependency, necessitating reforms like streamlined approval processes and boosting API self-sufficiency.

India, known as the 'Pharmacy of the World,' supplied vaccines and medicines globally during COVID-19, fulfilling 40% of U.S. generic drug demand and 25% of U.K. medicines. Mankind Pharma, a key player, expanded through strategic acquisitions. India's pharma industry faces regulatory challenges like complex approvals and API dependency, but reforms like streamlined processes and expanded PLI schemes could boost growth.